Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer
Eva Thomas(Cornell University), Miguel Martín(Hospital General Universitario Gregorio Marañón), P. Fumoleau(Institut Curie), Josep Tabernero(Deaconess Hospital), Aňa Lluch(Hospital Clínico Universitario de Valencia), Valentina Guarneri(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Linda T. Vahdat(Dartmouth–Hitchcock Medical Center), David Lebwohl(Intellia Therapeutics (United States)), Judith Klimovsky(National Cancer Center), Valerie Poulart(Cornell University), Howard A. Burris(Deaconess Hospital), Edgardo Rivera(Cornell University), Craig A. Bunnell(Cornell University), Patrice Viens(Centre National de la Recherche Scientifique), José Baselga(Harvard University), Monica Fornier(Cornell University)
Cited by 290
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
|Journal of Clinical Oncology|1997|5.9k
The landscape of somatic copy-number alteration across human cancers
|Nature|2010|4.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k